Oxford Cannabinoid Technologies, a company focused on drug development, reported strong results in their half-year report. The CEO, Clarissa Sowememo-Coker, highlighted:
– Oxford Cannabinoid Technologies reported strong results in their half-year report
– On track and on budget for phase one of their program, with results expected in Q2
– Preclinical work with Evotec SE was completed in December
– Signed a Phase one clinical trial provider, Simbec
– Made progress on their other drug development programs, including program three and four
– Continues to manage cash carefully and ended the period with 5 million in cash, extending their runway to Q1 of 2024
– Emphasised the importance of R&D tax relief for their company